{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:52:28Z","timestamp":1790751148259,"version":"4.1.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.trecan.2017.05.001","type":"journal-article","created":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T16:15:18Z","timestamp":1495728918000},"page":"482-490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["ADAM Metalloprotease-Released Cancer Biomarkers"],"prefix":"10.1016","volume":"3","author":[{"given":"Peter","family":"Herrlich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Herrlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2017.05.001_bib0005","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.2174\/1389450117666160727143618","article-title":"Targeting ADAM17 sheddase activity in cancer","volume":"17","author":"Rossello","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.trecan.2017.05.001_bib0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1021\/pr100556z","article-title":"Active metalloproteases of the A Disintegrin and Metalloprotease (ADAM) family: biological function and structure","volume":"10","author":"Klein","year":"2011","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.trecan.2017.05.001_bib0015","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrc2459","article-title":"The ADAMs: signalling scissors in the tumour microenvironment","volume":"8","author":"Murphy","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2017.05.001_bib0020","doi-asserted-by":"crossref","first-page":"e54412","DOI":"10.1371\/journal.pone.0054412","article-title":"Systemic overexpression of TNF\u03b1-converting enzyme does not lead to enhanced shedding activity in vivo","volume":"8","author":"Yoda","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.trecan.2017.05.001_bib0025","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.tibs.2012.12.002","article-title":"Who decides when to cleave an ectodomain?","volume":"38","author":"Hartmann","year":"2013","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.trecan.2017.05.001_bib0030","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1084\/jem.20072602","article-title":"Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages","volume":"205","author":"Sierra","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.trecan.2017.05.001_bib0035","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12026-013-8434-7","article-title":"Tumor necrosis factor-alpha-converting enzyme activities and tumor-associated macrophages in breast cancer","volume":"58","author":"Rego","year":"2014","journal-title":"Immunol. Res."},{"key":"10.1016\/j.trecan.2017.05.001_bib0040","doi-asserted-by":"crossref","first-page":"6899","DOI":"10.1074\/jbc.M609570200","article-title":"MT1-MMP controls tumor-induced angiogenesis through the release of semaphorin 4D","volume":"282","author":"Basile","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.trecan.2017.05.001_bib0045","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/nature04186","article-title":"VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche","volume":"438","author":"Kaplan","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2017.05.001_bib0050","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ccell.2016.09.011","article-title":"Characteristics and significance of the pre-metastatic niche","volume":"30","author":"Liu","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2017.05.001_bib0055","doi-asserted-by":"crossref","first-page":"948501","DOI":"10.1155\/2015\/948501","article-title":"Human tumor antigens and cancer immunotherapy","volume":"2015","author":"Vigneron","year":"2015","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.trecan.2017.05.001_bib0060","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1602\/neurorx.1.2.182","article-title":"Biomarkers: potential uses and limitations","volume":"1","author":"Mayeux","year":"2004","journal-title":"NeuroRx"},{"key":"10.1016\/j.trecan.2017.05.001_bib0065","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s10147-016-1049-y","article-title":"Recent progress and perspectives on prostate cancer biomarkers","volume":"22","author":"Hatakeyama","year":"2017","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2017.05.001_bib0070","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1074\/mcp.R200007-MCP200","article-title":"The human plasma proteome: history, character, and diagnostic prospects","volume":"1","author":"Anderson","year":"2002","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.trecan.2017.05.001_bib0075","first-page":"2","article-title":"Considerations for the use of blood plasma and serum for proteomic analysis","volume":"1","author":"Lundblad","year":"2005","journal-title":"Internet J. Genomics Proteomics"},{"key":"10.1016\/j.trecan.2017.05.001_bib0080","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/path.1814","article-title":"Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells","volume":"207","author":"Blanchot-Jossic","year":"2005","journal-title":"J. Pathol."},{"key":"10.1016\/j.trecan.2017.05.001_bib0085","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/annonc\/mds279","article-title":"ADAM-17: a novel therapeutic target for triple negative breast cancer","volume":"24","author":"McGowan","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2017.05.001_bib0090","doi-asserted-by":"crossref","first-page":"9530","DOI":"10.1073\/pnas.1233633100","article-title":"Clusterin as a biomarker in murine and human intestinal neoplasia","volume":"100","author":"Chen","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2017.05.001_bib0095","doi-asserted-by":"crossref","first-page":"e1003250","DOI":"10.1371\/journal.pgen.1003250","article-title":"DNA-methylome analysis of mouse intestinal adenoma identifies a tumour-specific signature that is partly conserved in human colon cancer","volume":"9","author":"Grimm","year":"2013","journal-title":"PLoS Genet."},{"key":"10.1016\/j.trecan.2017.05.001_bib0100","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian cancer development and metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.trecan.2017.05.001_bib0105","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1365-2249.2010.04298.x","article-title":"ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers","volume":"163","author":"Sinnathamby","year":"2011","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.trecan.2017.05.001_bib0110","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s12094-015-1283-1","article-title":"Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy","volume":"17","author":"Aydin","year":"2015","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.trecan.2017.05.001_bib0115","doi-asserted-by":"crossref","first-page":"9045","DOI":"10.1158\/0008-5472.CAN-05-3287","article-title":"Aberrant expression of a disintegrin and metalloproteinase 17\/tumor necrosis factor-alpha converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma","volume":"66","author":"Ringel","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2017.05.001_bib0120","doi-asserted-by":"crossref","first-page":"11633","DOI":"10.1007\/s13277-016-5129-4","article-title":"Noninvasive detection of gastric cancer","volume":"37","author":"Wan","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.trecan.2017.05.001_bib0125","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/MPA.0000000000000368","article-title":"Early detection of sporadic pancreatic cancer: summative review","volume":"44","author":"Chari","year":"2015","journal-title":"Pancreas"},{"key":"10.1016\/j.trecan.2017.05.001_bib0130","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1021\/acs.jproteome.5b00499","article-title":"Metrics for the Human Proteome Project 2015: progress on the Human Proteome and Guidelines for High-Confidence Protein Identification","volume":"14","author":"Omenn","year":"2015","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.trecan.2017.05.001_bib0135","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1021\/acs.jproteome.6b00511","article-title":"Metrics for the Human Proteome Project 2016: progress on identifying and characterizing the human proteome, including post-translational modifications","volume":"15","author":"Omenn","year":"2016","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.trecan.2017.05.001_bib0140","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1021\/acs.jproteome.6b00444","article-title":"Highlights of the biology and disease-driven Human Proteome Project, 2015-2016","volume":"15","author":"Van Eyk","year":"2016","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.trecan.2017.05.001_bib0145","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nmeth.4153","article-title":"Building ProteomeTools based on a complete synthetic human proteome","volume":"14","author":"Zolg","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.trecan.2017.05.001_bib0150","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.celrep.2015.03.050","article-title":"The proteomic landscape of triple-negative breast cancer","volume":"11","author":"Lawrence","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.trecan.2017.05.001_bib0155","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jprot.2016.05.005","article-title":"A proteomic signature of ovarian cancer tumor fluid identified by highthroughput and verified by targeted proteomics","volume":"145","author":"Poersch","year":"2016","journal-title":"J. Proteomics"},{"key":"10.1016\/j.trecan.2017.05.001_bib0160","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s12967-015-0668-9","article-title":"Identification of serum proteome signatures of locally advanced and metastatic gastric cancer: a pilot study","volume":"13","author":"Abramowicz","year":"2015","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.trecan.2017.05.001_bib0165","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cca.2014.02.001","article-title":"Serum proteomics for gastric cancer","volume":"431","author":"Liu","year":"2014","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.trecan.2017.05.001_bib0170","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jprot.2014.01.001","article-title":"Colorectal cancer candidate biomarkers identified by tissue secretome proteome profiling","volume":"99","author":"de Wit","year":"2014","journal-title":"J. Proteomics"},{"key":"10.1016\/j.trecan.2017.05.001_bib0175","doi-asserted-by":"crossref","first-page":"8283","DOI":"10.3748\/wjg.v22.i37.8283","article-title":"Recent advances in mass spectrometry-based proteomics of gastric cancer","volume":"22","author":"Kang","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.trecan.2017.05.001_bib0180","doi-asserted-by":"crossref","first-page":"804","DOI":"10.2174\/1381612822666151209151848","article-title":"A proteomics based approach for the identification of gastric cancer related markers","volume":"22","author":"Sheikh","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.trecan.2017.05.001_bib0185","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nature19949","article-title":"Mass-spectrometric exploration of proteome structure and function","volume":"537","author":"Aebersold","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2017.05.001_bib0190","doi-asserted-by":"crossref","first-page":"10513","DOI":"10.1073\/pnas.0804549105","article-title":"Circulating microRNAs as stable blood-based markers for cancer detection","volume":"105","author":"Mitchell","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2017.05.001_bib0195","first-page":"103","article-title":"Tumor cell-derived exosomes: a message in a bottle","volume":"1826","author":"Kharaziha","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.trecan.2017.05.001_bib0200","doi-asserted-by":"crossref","first-page":"10830","DOI":"10.1021\/acs.analchem.5b02063","article-title":"Multiplexed targeted mass spectrometry-based assays for the quantification of N-linked glycosite-containing peptides in serum","volume":"87","author":"Thomas","year":"2015","journal-title":"Anal. Chem."},{"key":"10.1016\/j.trecan.2017.05.001_bib0205","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nature15756","article-title":"Tumour exosome integrins determine organotropic metastasis","volume":"527","author":"Hoshino","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2017.05.001_bib0210","doi-asserted-by":"crossref","first-page":"731479","DOI":"10.1155\/2015\/731479","article-title":"Challenges in using circulating miRNAs as cancer biomarkers","volume":"2015","author":"Tiberio","year":"2015","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.trecan.2017.05.001_bib0215","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3233\/BLC-160054","article-title":"A systematic review of the diagnostic and prognostic value of urinary protein biomarkers in urothelial bladder cancer","volume":"2","author":"D\u2019Costa","year":"2016","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.trecan.2017.05.001_bib0220","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1002\/elps.201600258","article-title":"High-throughput miRNA sequencing and identification of biomarkers for forensically relevant biological fluids","volume":"37","author":"Seashols-Williams","year":"2016","journal-title":"Electrophoresis"},{"key":"10.1016\/j.trecan.2017.05.001_bib0225","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/cancers9010008","article-title":"Exosomes in cancer diagnostics","volume":"9","author":"Soung","year":"2017","journal-title":"Cancers"},{"key":"10.1016\/j.trecan.2017.05.001_bib0230","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/glycob\/cwj091","article-title":"Approaches to the study of N-linked glycoproteins in human plasma using lectin affinity chromatography and nano-HPLC coupled to electrospray linear ion trap\u2013Fourier transform mass spectrometry","volume":"16","author":"Wang","year":"2006","journal-title":"Glycobiology"},{"key":"10.1016\/j.trecan.2017.05.001_bib0235","doi-asserted-by":"crossref","first-page":"10670","DOI":"10.1021\/ac401812b","article-title":"Solid phase extraction of N-linked glycopeptides using hydrazide tip","volume":"85","author":"Chen","year":"2013","journal-title":"Anal. Chem."},{"key":"10.1016\/j.trecan.2017.05.001_bib0240","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1021\/acs.jproteome.5b00315","article-title":"A combined shotgun and targeted mass spectrometry strategy for breast cancer biomarker discovery","volume":"14","author":"Sj\u00f6str\u00f6m","year":"2015","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.trecan.2017.05.001_bib0245","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.15252\/emmm.201404873","article-title":"Prediction of colorectal cancer diagnosis based on circulating plasma proteins","volume":"7","author":"Surinova","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.trecan.2017.05.001_bib0250","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/jcb.25413","article-title":"Translational research and plasma proteomic in cancer","volume":"117","author":"Santini","year":"2016","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.trecan.2017.05.001_bib0255","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/anie.201609108","article-title":"Coupling sensitive nucleic acid amplification with commercial pregnancy test strips","volume":"56","author":"Du","year":"2017","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.trecan.2017.05.001_bib0260","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.1158\/1078-0432.CCR-10-0119","article-title":"A combination of serum markers for the early detection of colorectal cancer","volume":"16","author":"Wild","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2017.05.001_bib0265","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.15252\/emmm.201404874","article-title":"Non-invasive prognostic protein biomarker signatures associated with colorectal cancer","volume":"7","author":"Surinova","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.trecan.2017.05.001_bib0270","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nature06916","article-title":"Mining the plasma proteome for cancer biomarkers","volume":"452","author":"Hanash","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2017.05.001_bib0275","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.cgh.2016.02.008","article-title":"Molecular biomarkers in the personalized treatment of colorectal cancer","volume":"14","author":"Sinicrope","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.trecan.2017.05.001_bib0280","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.6004\/jnccn.2016.0109","article-title":"Biomarkers in colorectal cancer screening","volume":"14","author":"Nguyen","year":"2016","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.trecan.2017.05.001_bib0285","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1001\/jama.2016.5989","article-title":"Screening for colorectal cancer: US Preventive Services Task Force Recommendation Statement","volume":"315","author":"Bibbins-Domingo","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.trecan.2017.05.001_bib0290","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1053\/j.gastro.2012.03.022","article-title":"Efficacy of a nationwide screening colonoscopy program for colorectal cancer","volume":"142","author":"Pox","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.trecan.2017.05.001_bib0295","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1002\/cam4.806","article-title":"Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)","volume":"5","author":"Hatch","year":"2016","journal-title":"Cancer Med."},{"key":"10.1016\/j.trecan.2017.05.001_bib0300","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11523-013-0284-7","article-title":"EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan","volume":"9","author":"Loupakis","year":"2014","journal-title":"Target. Oncol."},{"key":"10.1016\/j.trecan.2017.05.001_bib0305","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1146\/annurev-med-042513-015127","article-title":"Targeting HER2 for the treatment of breast cancer","volume":"66","author":"Rimawi","year":"2015","journal-title":"Ann. Rev. Med."},{"key":"10.1016\/j.trecan.2017.05.001_bib0310","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1111\/bph.13211","article-title":"Therapeutic targets of triple-negative breast cancer: a review","volume":"172","author":"Jamdade","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.trecan.2017.05.001_bib0315","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.molonc.2010.11.003","article-title":"Deconstructing the molecular portraits of breast cancer","volume":"5","author":"Prat","year":"2011","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.trecan.2017.05.001_bib0320","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2087204","article-title":"The importance of CD44 as a stem cell biomarker and therapeutic target in cancer","volume":"2016","author":"Thapa","year":"2016","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.trecan.2017.05.001_bib0325","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.10.020","article-title":"Inhibition of tumor growth and metastasis in pancreatic cancer models by interference With CD44v6 signaling","volume":"150","author":"Matzke-Ogi","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.trecan.2017.05.001_bib0330","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s10549-011-1691-z","article-title":"Serum CD44 levels and overall survival in patients with HER2-positive breast cancer","volume":"130","author":"Baek","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.trecan.2017.05.001_bib0335","first-page":"2995","article-title":"Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer","volume":"21","author":"Kopp","year":"2001","journal-title":"Anticancer Res."},{"key":"10.1016\/j.trecan.2017.05.001_bib0340","first-page":"2703","article-title":"Circulating HER-2\/erbB-2\/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662","volume":"7","author":"Hayes","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2017.05.001_bib0345","first-page":"541","article-title":"Study of the measurement of serum extracellular domain of HER-2\/neu protein with CLIA method. Rinsho byori","volume":"58","author":"Kuroda","year":"2010","journal-title":"Jpn. J. Clin. Pathol."},{"key":"10.1016\/j.trecan.2017.05.001_bib0350","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000059706","article-title":"Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy","volume":"23","author":"Classen","year":"2002","journal-title":"Tumour Biol."},{"key":"10.1016\/j.trecan.2017.05.001_bib0355","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1373\/49.10.1579","article-title":"Potential clinical utility of serum HER-2\/neu oncoprotein concentrations in patients with breast cancer","volume":"49","author":"Carney","year":"2003","journal-title":"Clin. Chem."},{"key":"10.1016\/j.trecan.2017.05.001_bib0360","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/cncr.28130","article-title":"Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831","volume":"119","author":"Moreno-Aspitia","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.trecan.2017.05.001_bib0365","first-page":"1479","article-title":"Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer","volume":"26","author":"M\u00fcller","year":"2006","journal-title":"Anticancer Res."},{"key":"10.1016\/j.trecan.2017.05.001_bib0370","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/172460080602100301","article-title":"Clinical utility of determination of HER-2\/neu and EGFR fragments in serum of patients with metastatic breast cancer","volume":"21","author":"Witzel","year":"2006","journal-title":"Int. J. Biol. Markers"},{"key":"10.1016\/j.trecan.2017.05.001_bib0375","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1309\/51KPD70348RP6XTE","article-title":"The predictive value of EGFR and HER-2\/neu in tumor tissue and serum for response to anthracycline-based neoadjuvant chemotherapy of breast cancer","volume":"128","author":"Schippinger","year":"2007","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.trecan.2017.05.001_bib0380","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ejca.2005.08.036","article-title":"Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer","volume":"42","author":"Hudelist","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.trecan.2017.05.001_bib0385","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1093\/annonc\/mdi393","article-title":"Gefitinib (ZD 1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate","volume":"16","author":"Gasparini","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2017.05.001_bib0390","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/sji.12072","article-title":"Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications","volume":"78","author":"Chitadze","year":"2013","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.trecan.2017.05.001_bib0395","doi-asserted-by":"crossref","first-page":"e1093276","DOI":"10.1080\/2162402X.2015.1093276","article-title":"NKG2D- and T-cell receptor-dependent lysis of malignant glioma cell lines by human \u03b3\u03b4 T cells: modulation by temozolomide and A disintegrin and metalloproteases 10 and 17 inhibitors","volume":"5","author":"Chitadze","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.trecan.2017.05.001_bib0400","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.4049\/jimmunol.1200796","article-title":"Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses","volume":"189","author":"Hilpert","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.trecan.2017.05.001_bib0405","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.2741\/2939","article-title":"Soluble NKG2D ligands: prevalence, release, and functional impact","volume":"13","author":"Salih","year":"2008","journal-title":"Front. Biosci."},{"key":"10.1016\/j.trecan.2017.05.001_bib0410","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1158\/0008-5472.CAN-04-0811","article-title":"Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy","volume":"64","author":"Miyamoto","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2017.05.001_bib0415","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/bjc.2015.21","article-title":"Protein shedding in urothelial bladder cancer: prognostic implications of soluble urinary EGFR and EpCAM","volume":"112","author":"Bryan","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.trecan.2017.05.001_bib0420","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1016\/j.yexcr.2008.07.013","article-title":"Shedding of epidermal growth factor receptor is a regulated process that occurs with overexpression in malignant cells","volume":"314","author":"Perez-Torres","year":"2008","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.trecan.2017.05.001_bib0425","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00432-008-0397-z","article-title":"Increased soluble CD44 concentrations are associated with larger tumor size and lymph node metastasis in breast cancer patients","volume":"134","author":"Mayer","year":"2008","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.trecan.2017.05.001_bib0430","doi-asserted-by":"crossref","first-page":"e90461","DOI":"10.1371\/journal.pone.0090461","article-title":"A soluble form of the giant cadherin Fat1 is released from pancreatic cancer cells by ADAM10 mediated ectodomain shedding","volume":"9","author":"Wojtalewicz","year":"2014","journal-title":"PLoS One"}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803317300870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803317300870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T12:51:59Z","timestamp":1535806319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803317300870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":86,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S2405803317300870"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2017.05.001","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ADAM Metalloprotease-Released Cancer Biomarkers","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2017.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}